Cell 4.17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Karen M. Hauda

Group

1632

Applicants

R. Kucherlapati et al.

Serial No.

08/724,752

Filed

October 2, 1996

For

HUMAN ANTIBODIES DERIVED FROM

IMMUNIZED XENOMICE

New York, New York December 15, 1999

Hon. Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Statement and a completed Form PTO-1449 (with copies of certain documents listed thereon) in the above-identified application. This Statement is submitted after the mailing date of a first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a Notice of Allowance under 37 C.F.R. § 1.311.

Accordingly, pursuant to 37 C.F.R. § 1.98, please charge the fee set forth in 37 C.F.R. § 1.17(p) to Account No. 06-1075.

The Commissioner is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the Information Disclosure Statement transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this letter is transmitted herewith.

Respectfully submitted,

James F. Haley, Jrv (Reg. No. 27,794)
Jane T. Gunnison (Reg. No. 38,479)
Attorneys for Applicants

c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

CELL 4.17

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Karen M. Hauda

Group : 1632

Applicants : R. Kucherlapati et al.

Serial No. : 08/724,752

Filed : October 2, 1996

For : HUMAN ANTIBODIES DERIVED FROM

IMMUNIZED XENOMICE

New York, New York December 15, 1999

Hon. Assistant Commissioner for Patents Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. SS 1.56 AND 1.97

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents which are listed on the enclosed Form PTO-1449.

UNITED STATES PATENT DOCUMENTS

United States patent 4,950,599 (Bertling et al.), issued August 21, 1990;

United States patent 4,959,313 (Taketo et al.), issued September 25, 1990;

United States patent 5,204,244 (Fell et al.), issued April 20, 1993:

United States patent 5,545,806 (Lonberg et al.), issued August 13, 1996;

United States patent 5,545,807 (Surani et al.), issued August 13, 1996;

United States patent 5,569,825 (Lonberg al.), issued October 29, 1996;

FOREIGN PATENT DOCUMENTS

PCT Publication WO 90/04036, published April 19, 1990;
PCT Publication WO 91/00906, published January 24, 1991;**

PCT Publication WO 91/10741, published July 25, 1991;

PCT Publication WO 92/03918, published March 19, 1992;

PCT Publication WO 93/05165, published March 18, 1993;

PCT Publication WO 94/00569, published January 6, 1994;

PCT Publication WO 94/02602, published February 3, 1994;

European Patent EP 298 807, published January 11, 1989;

European Patent EP 315 062, published May 10, 1989;*

European Patent EP 322 240, published June 28, 1989;

European Patent Application EP A 459 372, published December 4, 1991;

European Patent EP 463 151, published January 2, 1992; **

OTHER DOCUMENTS

Albertsen et al., "Construction and Characterization of a Yeast Artificial Chromosome Library Containing Seven Haploid Human Genome Equivalents," Proc. Natl. Acad. Sci., 87, pp. 4256-4260 (1990);

Aldhous, "Transgenic mice display a class (switching) act," Science 262:1212-1213 (1993);

^{*} European patent 315 062 is the counterpart to United States patent 5,204,244, cited herein.

^{**} Copy enclosed. European Patent 453 151 corresponds to PCT publication WO 91/10741.

Ayares et al., "Sequence Homology Requirements for Intermolecular Recombination in Mammalian Cells," *Proc. Natl. Acad. Sci.*, 83, pp. 5199-5203 (1986);

Berman et al., "Content and Organization of the Human Ig VH Locus: Definition of Three New VH Families and LInkage to the Ig CH Locus," EMBO J., 7, pp. 727-738 (1988);

Blankenstein and Kruwinkel, Eur. J. Immunol., 17, pp. 1351-1357 (1987);

Brinster et al., "Introns Increase Transcriptional Efficiency in Transgenic Mice," Proc. Natl. Acad. Sci., 85, pp. 836-840 (1988);

Brownstein et al., "Isolation of Single-Copy Human Genes From a Library of Yeast Artificial Chromosome Clones," Science, 244, pp. 1348-1351 (1989);

Bruggemann et al., "A Repertoire of Monoclonal Antibodies with Human Heavy Chains from Transgenic Mice," Proc. Natl. Acad. Sci., 86, pp. 6709-6713 (1989);

Bruggemann et al., "Construction, Function and Immunogenicity of Recombinant Monoclonal Antibodies," Behring Inst. Mitt., 87, pp. 21-24 (1990);

Bruggemann et al., "Human Antibody Production in Transgenic Mice: Expression from 100 kb of the Human IgH Locus," Eur. J. Immunolog., 21, pp. 1323-1326 (1991);

Burke et al., "Cloning of Large Segments of Exogenous DNA Into Yeast By Means of Artificial Chromosome Vectors," Science, 236, pp. 806-812 (1987);

Buttin, G, "Exogenous IgGene Rearrangement in Transgenic Mice: A New Strategy for Human Monoclonal Antibody Production," Trends in Genetics, 3, pp. 205-206 (1987)

Capecchi et al., "Altering The Genome By Homologous Recombination," Science, 244, pp. 1288-92 (1989);

Choi et al., "RNA Splicing Generates A Variant Light Chain From An Aberrantly Arranged & Gene," Nature, 286, pp. 776-779 (1980);

Choi, et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," Nature Genetics 4:117-123 (1993);**

Davies et al., "Targeted Alterations in Yeast Artificial Chromosomes for Inter-Species Gene Transfer," Nucl. Acid Res., 20, pp. 2693-2698 (1992);

Dorfman, N.A., "The Optimal Technological Approach to the Development of Human Hybridomas," J. Biol. Response Modifiers, 4, pp. 213-239 (1985);

Doetschman et al, "Targeted Mutation Of The HPRT Gene In Mouse Embryonic Stem Cells," Proc. Natl. Acad. Sci., 85, pp. 8583-8587 (1988);

Eliceiri et al., "Stable Integration and Expression In Mouse Cells of Yeast Artificial Chromosomes Harboring Human Genes," Proc. Natl. Acad. Sci., 88, pp. 2179-2183 (1991);

Emery, S.C. and Adair, J.R., "Humanised Monoclonal Antibodies for Therapeutic Applications," Expert Opinion on Investigation Drugs, 3, pp. 241-251 (1994); **

Garza et al., "Mapping the Drosophila Genome With Yeast Artificial Chromosomes," Science, 246, pp. 641-646 (1989);

Gnirke et al., "Cloning and in vivo expression of the Human GART Gene Using Yeast Artificial Chromosomes," EMBO J., 10, pp. 1629-1634 (1991);

Green, L.L. et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," Nat Genet. 7, pp. 13-21 (1994);**

Huxley et al., "The Human HPRT Gene on a Yeast Artificial Chromosome Is Functional When Transferred to Mouse Cells by Cell Fusion," Genomics, 9, pp. 742-750 (1991);

Jakobovits et al., "Germ-line Transmission and Expression of A Human-derived Yeast Artificial Chromosome," Nature, 362, pp. 252-258 (1993);

Johnson et al., "Targeting Of Nonexpressed Genes In Embryonic Stem Cells Via Homologous Recombination," Science, 245, pp. 1234-1236 (1989);

Joyner et al., "Production of a Mutation in Mouse En-2 Gene By Homologous Recombination," Nature, 338, pp. 153-155 (1989);

Koller et al., "Inactivating the B2-Microglobulin Locus in Mouse Embryonic Stem Cells by Homologous Recombination," Proc. Natl. Acad. Sci., 86, pp. 8932-8935 (1989);

Kucherlapati et al., "Homologous Recombination in Mammalian Somatic Cells," Prog. Nucleic Acid Res. Mol. Biol., 36, pp. 301-310 (1989);

Mansour et al., "Disruption of the Proto-oncogene Int-2 In Mouse Embryo-derived Stem Cells: A General Strategy For Targeting Mutations To Non-selectable Genes," Nature, 336, pp. 348-352 (1988);

Matsuda et al., "Structure and Physical Map of 64 Variable Segments in the 3' 0.8 Megabase REgion of the Human Immunoglobulin Heavy-Chain Locus," Nature Genetics, 3, pp. 88-94 (1993);

Max et al., "Sequences of Five Potential Recombination Sites Encoded Close To An Immunoglobulin & Constant Region Gene," Proc. Natl. Acad. Sci., 76, pp. 3450-3454 (1979);

Miller et al., "Structural Alterations in J regions of Mouse Immunoglobulin λ Genes Are Associated With Diufferential Gene Expression," Nature, 295, pp. 428-430 (1982);

Morrison, S. "Success is in the Specification," Nature, 369, pp. 812-813 (1994);**

Mortensen et al., "Production of Homozygous Mutant ES Cells with a Songle Targeting Construct," Mol. and Cell Biol., 12, pp. 2391-2395 (1992);

Orkin et al., "Mutation In An Intervening Sequence Splice Junction In Man," Proc. Natl. Acad. Sci., 78, pp. 5041-5045 (1981);

Pachnis et al., Proc. Natl. Acad. Sci., 87, pp. 5109-5113 (1990);

Pavan et al., "Modification and Transfer into an Embryonal Carcinoma Cell Line of a 360 kb Human-Derived Yeast Artificial Chromosome," Mol. and Cell. Biol., 10, pp. 4163-4169 (1990);

Rajewski et al., "Evolutionary and Somatic Selection of the Antibody Repertoire in the Mouse," Science, 238, pp. 1088-1094 (1987);

Ramirez-Solis et al., "Chromosome Engineering In Mice," Nature, 378, pp. 720-724 (1995);

Sakano et al., "Sequences At The Somatic Recombination Sites Of Immunoglobulin Light-Chain Genes," *Nature*, 280, pp. 288-294 (1979);

Sakano et al., "Two Types Of Somatic Recombination Are Necessary For The Generation Of Complete Immunoglobulin Heavy-Chain Genes," Nature, 286, pp. 676-683 (1980);

Sakano et al., "Identifiation and Nucleotide Sequence of a Diversity DNA Segment (D) of Immunoglobulin Heavy-Chain Genes," Nature, 290, pp. 562-565 (1981);

Schedl et al, "Transgenic Mice Generated By Pronuclear Injection Of A Yeast Artificial Chromosome," Nucl. Acid Res., 20, pp. 3073-3077 (1992);

Schedl, et al., "A method for the generation of YAC transgenic mice by pronuclear microinjection," Nucleic Acids Research 21(20):4783-4787 (1993);**

Schedl, et al., "A yeast artificial chromosome covering the tyrosinase gene confers copy number-dependent expression in transgenic mice," Nature 362:258-261 (1993);

Schwartzberg et al., "Germ-line Transmission Of A c-abl Mutation Produced By Targeted Gene Disruption In ES Cells," Science, 246, pp. 799-803 (1989);

Seidman and Leder, "A Mutant Immunoglobulin Light Chain Is Formed By Aberrant DNA- and RNA-Splicing Events," Nature, 286, pp. 779-783 (1980);

Shimizu et al., "Immunoglobulin Double-Isotype Expression by Trans-mRNA in a Human Immunoglobulin Transgenic Mouse," Proc. Natl. Acad. Sci., 86, pp. 8020-8023 (1989);

Shin et al., "Physical Map of the 3' Region of the Human Immunoglobulin Heavy Chain Locus: Clustering of Autoantibody-Related Variable Segments in one Haplotype," EMBO J., 10, pp. 3641-3645 (1991);

Taggart et al., "Stable Antibody-Producing Murine Hybridomas," Science, 219, pp. 1228-1230 (1983);

Thomas et al., "Site-Directed Mutagenesis by Gene Targeting in Mouse Embryo-Derived Stem Cells," Cell, 51, pp. 503-512 (1987);

Traver et al., Proc. Natl. Acad. Sci., 86, pp. 5898-5902 (1989);

Treisman et al., "Specific Transcription and RNA Splicing Defects In Five Cloned β -Thalassaemia Genes," Nature, 302, pp. 591-596 (1983);

Tucker et al., "Mouse IgA Heavy Chain Gene Sequence: Implications for Evolution of Immunoglobulin Hinge Exons," Proc. Natl. Acad. Sci., 78, pp. 7684-7688 (1981);

Yamamura et al., Proc. Natl. Acad. Sci., 83, pp. 2152-2156 (1986);

Yancopoulos et al, "Reconstruction of an Immune System," Science, 241, pp. 1581-1583 (1988);

Zachau, "The Human Immunoglobulin K Locus and Some of its Acrobatics," Biol.chem., 371, pp. 1-6 (1990);

Zjilstra et al., "Germ-line Transmission Of A Disrupted β2-Microglobulin Gene Produced By Homologous Recombination In Embryonic Stem Cells," Nature, 342, pp.435-438 (1989);

Applicants have enclosed copies of the documents indicated with a double asterisk. Copies of the other documents were previously submitted in connection with United States application 07,922,649, now United States patent 5,939,598, and United States application 08/464,582, filed June 5, 1995. During a December 14, 1999 telephone call with applicants' attorney, Jane Gunnison, the Examiner indicated that applicants did not need to submit herewith copies of the previously submitted documents. However, applicants stand ready to do so at the request of the Examiner.

Applicants request that the cited documents be (1) fully considered by the Examiner during the course of

examination of this application and (2) printed on any patent issuing from this application.

Applicants are submitting this statement after mailing of an Office Action on the merits but before the mailing of a final Office Action or a Notice of Allowance. Accordingly, pursuant to 37 C.F.R. § 1.98, please charge the fee set forth in 37 C.F.R. § 1.17(p) to Account No. 06-1075. A duplicate of this paper is enclosed.

Respectfully submitted,

James F. Haley, Jr. (Reg. No. 27,794)

Jane T. Gunnison (Reg. No. 38,479)

Attorneys for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas New York, New York 10020-1104

Tel.: (212) 596-9000